Literature DB >> 26136920

Recurrent pulmonary synovial sarcoma effectively treated with amrubicin: A case report.

Hiroaki Satoh1, Norio Takayashiki2, Toshihiro Shiozawa3, Kunihiko Miyazaki3, Gen Ohara1, Katsunori Kagohashi1, Koichi Kurishima1, Shintaro Sugita4, Tomoyuki Aoyama4, Tadashi Hasegawa4, Nobuyuki Hizawa3.   

Abstract

Pulmonary synovial sarcoma is a rare but aggressive disease. The present study describes the case of a 68-year-old female with pulmonary synovial sarcoma. The patient was mistakenly treated for small cell lung cancer due to false-positive staining for synaptophysin and cluster of differentiation 56. Despite severe myelotoxicity, platinum-containing chemotherapies (cisplatin plus irinotecan and carboplatin plus etoposide) were not effective. As a third-line therapy, the patient received amrubicin (AMR) monotherapy. A partial response was achieved, and the patient was able to undertake ordinary daily life at home for 13 months from the initiation of AMR chemotherapy. Due to the atypical clinical condition and unusual response to chemotherapy in this patient, the pathological examination was repeated. The SS18 split-signal was detected in fluorescence in situ hybridization analysis. From these results, the tumor was diagnosed as a monophasic synovial sarcoma. To the best of our knowledge, this is the first case of a patient with pulmonary synovial sarcoma who underwent successful treatment with AMR. The present case could demonstrate a specific chemosensitivity of such a rare tumor.

Entities:  

Keywords:  amrubicin; chemotherapy; pulmonary synovial sarcoma

Year:  2015        PMID: 26136920      PMCID: PMC4471737          DOI: 10.3892/etm.2015.2308

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  22 in total

1.  Soft tissue sarcomas of the extremities.

Authors:  Blake A Morrison
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-07

Review 2.  Amrubicin: a synthetic anthracyclin analogue in the treatment of extensive stage small cell lung cancer.

Authors:  Chirag M Shah
Journal:  Recent Pat Anticancer Drug Discov       Date:  2009-11       Impact factor: 4.169

3.  Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin.

Authors:  T Suzuki; S Minamide; T Iwasaki; H Yamamoto; H Kanda
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

4.  Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.

Authors:  Chiyoe Kitagawa; Hideo Saka; Shigehisa Kajikawa; Kouki Mori; Masahide Oki; Ryujiro Suzuki
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-12       Impact factor: 3.333

5.  Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

Authors:  Sayaka Onoda; Noriyuki Masuda; Takashi Seto; Kenji Eguchi; Yuichi Takiguchi; Hiroshi Isobe; Hiroaki Okamoto; Takashi Ogura; Akira Yokoyama; Nobuhiko Seki; Yoshiko Asaka-Amano; Masao Harada; Akihiro Tagawa; Hiroshi Kunikane; Masanori Yokoba; Kazutsugu Uematsu; Takayuki Kuriyama; Yumi Kuroiwa; Koshiro Watanabe
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

Review 6.  From the archives of the AFIP: Pleuropulmonary synovial sarcoma.

Authors:  Aletta Ann Frazier; Teri J Franks; Robert D Pugatch; Jeffrey R Galvin
Journal:  Radiographics       Date:  2006 May-Jun       Impact factor: 5.333

7.  Primary synovial sarcoma of the lung as an incidental finding.

Authors:  Stefan B Watzka; Ulrike Setinek; Helmut Prosch; Michael R Müller
Journal:  Interact Cardiovasc Thorac Surg       Date:  2009-09-22

8.  Primary pulmonary sarcomas with features of monophasic synovial sarcoma: a clinicopathological, immunohistochemical, and ultrastructural study of 25 cases.

Authors:  H Zeren; C A Moran; S Suster; N F Fishback; M N Koss
Journal:  Hum Pathol       Date:  1995-05       Impact factor: 3.466

9.  Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.

Authors:  T Noda; T Watanabe; A Kohda; S Hosokawa; T Suzuki
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

10.  Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer.

Authors:  Daiki Ogawara; Minoru Fukuda; Yoichi Nakamura; Shigeru Kohno
Journal:  Cancer Manag Res       Date:  2010-08-11       Impact factor: 3.989

View more
  1 in total

Review 1.  Diagnostic value of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in solitary mediastinal, hilar lymphadenectasis, or peribronchial lesions: Six cases reports and review of literature.

Authors:  Yan-Bin Chen; Jun-Hong Jiang; Jing-Yu Mao; Jian-An Huang
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.